A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer

CONCLUSIONS REPORTED BY THE RESEARCHERS?: The study showed that sacituzumab govitecan had significant anti-cancer activity. Though most participants who received sacituzumab govitecan experienced side effects, these did not usually stop participants from continuing sacituzumab govitecan. Doctors can help control these side effects using treatment guidelines, but these side effects can be serious. Clinical Trial Registration: NCT03547973 (ClinicalTrials.gov) (TROPHY-U-1).PMID:38682560 | DOI:10.2217/fon-2023-1030

Source: Ann Oncol - April 29, 2024 Category: Cancer & Oncology Authors: Yohann Loriot Arash Rezazadeh Kalebasty Aude Fl échon Rohit K Jain Sumati Gupta Manojkumar Bupathi Philippe Beuzeboc Phillip Palmbos Arjun V Balar Christos E Kyriakopoulos Damien Pouessel Cora N Sternberg Julia Tonelli Mitch Sierecki Huafeng Zhou Petros Source Type: research